Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8446597.
- Also identified by PMC identifier 45975.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Transcription of type 1 human immunodeficiency virus (HIV-1) provirus is governed by the viral long terminal repeat (LTR). Drugs can block HIV-1 replication by inhibiting activity of its LTR. We report that topotecan, beta-lapachone, and curcumin are potent and selective inhibitors of HIV-1 LTR-directed gene expression, at concentrations that have minor effects on cells. At these concentrations, each drug inhibited p24 antigen production in cells either acutely or chronically infected with HIV-1. Their target is transcriptional function of the LTR.
Medical subject headings
- Antiviral Agents
- Camptothecin
- Curcumin
- Gene Expression Regulation, Viral
- HIV Long Terminal Repeat
- HIV-1
- Naphthoquinones
- Virus Replication